Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
40
ACHV Quote, Financials, Valuation and Earnings
Last price:
$4.46
Seasonality move
:
15.53%
Day range:
$4.26 - $4.48
52-week range:
$1.84 - $5.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.06x
Volume:
420.9K
Avg. volume:
556.4K
1-year change:
17.68%
Market cap:
$237.4M
Revenue:
--
EPS (TTM):
-$1.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
-- | -$0.26 | -- | -22.76% | $15.38 |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$67.7M | $0.16 | 25.05% | 2133.71% | $16.67 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.05 | -- | -13.85% | $5.55 |
|
STME
StimCell Energetics, Inc.
|
-- | -- | -- | -- | -- |
|
VERO
Venus Concept, Inc.
|
$14.5M | -$0.92 | -3.5% | -54.23% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
$4.46 | $15.38 | $237.4M | -- | $0.00 | 0% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$16.29 | $16.67 | $2.1B | 29.03x | $0.00 | 0% | 8.65x |
|
EDSA
Edesa Biotech, Inc.
|
$1.30 | $11.00 | $9.1M | -- | $0.00 | 0% | 31.22x |
|
ONCY
Oncolytics Biotech, Inc.
|
$0.97 | $5.55 | $104.4M | -- | $0.00 | 0% | -- |
|
STME
StimCell Energetics, Inc.
|
$0.4100 | -- | $8.5M | -- | $0.00 | 0% | 1,937.12x |
|
VERO
Venus Concept, Inc.
|
$1.76 | -- | $3.3M | -- | $0.00 | 0% | 0.04x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
22.85% | 2.734 | 5.99% | 4.94x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
17.62% | -0.123 | 5.37% | 5.02x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -0.273 | -- | 10.60x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.153 | 0.41% | 1.61x |
|
STME
StimCell Energetics, Inc.
|
-54.35% | 4.095 | 8.86% | 0.00x |
|
VERO
Venus Concept, Inc.
|
92.44% | 0.662 | 689.6% | 0.48x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACHV
Achieve Life Sciences, Inc.
|
-$54K | -$14.7M | -139.57% | -189.88% | -- | -$11.3M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$65.3M | $30.7M | 17.52% | 21.42% | 41.75% | $44.9M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.9K | -$2.5M | -77.45% | -77.48% | -- | -$1.8M |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
STME
StimCell Energetics, Inc.
|
-- | -$254.1K | -- | -- | -- | -$108.1K |
|
VERO
Venus Concept, Inc.
|
$8.8M | -$9.5M | -129.08% | -1236.95% | -68.93% | -$4.9M |
Achieve Life Sciences, Inc. vs. Competitors
-
Which has Higher Returns ACHV or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of 42.95%. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M AUPHAurinia Pharmaceuticals, Inc.88.87% $0.23 $444M -
What do Analysts Say About ACHV or AUPH?
Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 256.73%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 2.82%. Given that Achieve Life Sciences, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Achieve Life Sciences, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.5 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is ACHV or AUPH More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.
-
Which is a Better Dividend Stock ACHV or AUPH?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or AUPH?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 29.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 8.65x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M AUPHAurinia Pharmaceuticals, Inc.8.65x 29.03x $73.5M $31.6M
-
Which has Higher Returns ACHV or EDSA?
Edesa Biotech, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Edesa Biotech, Inc.'s return on equity of -77.48%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M EDSAEdesa Biotech, Inc.-- -$0.32 $12.5M -
What do Analysts Say About ACHV or EDSA?
Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 256.73%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 746.15%. Given that Edesa Biotech, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.5 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is ACHV or EDSA More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.078, suggesting its less volatile than the S&P 500 by 92.204%.
-
Which is a Better Dividend Stock ACHV or EDSA?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or EDSA?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Edesa Biotech, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns ACHV or ONCY?
Oncolytics Biotech, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About ACHV or ONCY?
Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 256.73%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 472.27%. Given that Oncolytics Biotech, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.5 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is ACHV or ONCY More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.
-
Which is a Better Dividend Stock ACHV or ONCY?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or ONCY?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns ACHV or STME?
StimCell Energetics, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of --. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat StimCell Energetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M STMEStimCell Energetics, Inc.-- -$0.01 -$903.1K -
What do Analysts Say About ACHV or STME?
Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 256.73%. On the other hand StimCell Energetics, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Achieve Life Sciences, Inc. has higher upside potential than StimCell Energetics, Inc., analysts believe Achieve Life Sciences, Inc. is more attractive than StimCell Energetics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.5 0 0 STMEStimCell Energetics, Inc.0 0 0 -
Is ACHV or STME More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison StimCell Energetics, Inc. has a beta of 48.081, suggesting its more volatile than the S&P 500 by 4708.057%.
-
Which is a Better Dividend Stock ACHV or STME?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. StimCell Energetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. StimCell Energetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or STME?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than StimCell Energetics, Inc. quarterly revenues of --. Achieve Life Sciences, Inc.'s net income of -$14.4M is lower than StimCell Energetics, Inc.'s net income of -$265.6K. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while StimCell Energetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 1,937.12x for StimCell Energetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M STMEStimCell Energetics, Inc.1,937.12x -- -- -$265.6K
-
Which has Higher Returns ACHV or VERO?
Venus Concept, Inc. has a net margin of -- compared to Achieve Life Sciences, Inc.'s net margin of -163.68%. Achieve Life Sciences, Inc.'s return on equity of -189.88% beat Venus Concept, Inc.'s return on equity of -1236.95%.
Company Gross Margin Earnings Per Share Invested Capital ACHVAchieve Life Sciences, Inc.-- -$0.28 $43.6M VEROVenus Concept, Inc.64% -$12.14 $35.8M -
What do Analysts Say About ACHV or VERO?
Achieve Life Sciences, Inc. has a consensus price target of $15.38, signalling upside risk potential of 256.73%. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 6525%. Given that Venus Concept, Inc. has higher upside potential than Achieve Life Sciences, Inc., analysts believe Venus Concept, Inc. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACHVAchieve Life Sciences, Inc.5 0 0 VEROVenus Concept, Inc.0 1 0 -
Is ACHV or VERO More Risky?
Achieve Life Sciences, Inc. has a beta of 1.690, which suggesting that the stock is 68.981% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.
-
Which is a Better Dividend Stock ACHV or VERO?
Achieve Life Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Achieve Life Sciences, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACHV or VERO?
Achieve Life Sciences, Inc. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. Achieve Life Sciences, Inc.'s net income of -$14.4M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, Achieve Life Sciences, Inc.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Achieve Life Sciences, Inc. is -- versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACHVAchieve Life Sciences, Inc.-- -- -- -$14.4M VEROVenus Concept, Inc.0.04x -- $13.8M -$22.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
